Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Kenta Biotech today announced an agreement with Rentschler Biotechnologie for the development of a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).

“We are excited to work with Kenta on the clinical development of this promising product”

Using Kenta’s proprietary hybridoma cell line, Rentschler will develop a manufacturing process for Kenta’s KBSA301 antibody using, for the first time, single-use bioreactor technology.

“We are excited to work with Kenta on the clinical development of this promising product,” said Dr Nikolaus F. Rentschler, Chief Executive Officer of Rentschler Biotechnologie. “It will be a pleasure to complement Kenta’s knowledge with our experience in manufacturing biological drugs and we are looking forward to a successful partnership.”

“Rentschler manufactures biopharmaceuticals to exacting standards and will be a key partner for us as we progress the development of a much-needed treatment,” added Kenta’s Chief Executive Officer Violetta Georgescu-Kyburz.

KBSA301 is a fully human IgG antibody designed to treat infections caused by MRSA, a type of bacteria that can become resistant to certain antibiotics, including methicillin, oxacillin, penicillin and amoxicillin. KBSA301 has shown in several preclinical animal models that the antibody is very effective in treating severe S. aureus infections.